Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 2/2013

01-02-2013 | Erratum

Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

Authors: Bojana Milojkovic Kerklaan, Veronique Diéras, Christophe Le Tourneau, Marja Mergui-Roelvink, Alwin D. R. Huitema, Hilde Rosing, Jos H. Beijnen, Sandrine Marreaud, Anne-Sophie Govaerts, Martine J. Piccart-Gebhart, Jan H. M. Schellens, Ahmad Awada

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2013

Login to get access

Excerpt

Unfortunately, one of the co-author’s (Bojana Milojkovic Kerklaan) family name was published wrongly in the original version of the article. The correct family name is Milojkovic Kerklaan. …
Metadata
Title
Erratum to: Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
Authors
Bojana Milojkovic Kerklaan
Veronique Diéras
Christophe Le Tourneau
Marja Mergui-Roelvink
Alwin D. R. Huitema
Hilde Rosing
Jos H. Beijnen
Sandrine Marreaud
Anne-Sophie Govaerts
Martine J. Piccart-Gebhart
Jan H. M. Schellens
Ahmad Awada
Publication date
01-02-2013
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 2/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-012-2064-y

Other articles of this Issue 2/2013

Cancer Chemotherapy and Pharmacology 2/2013 Go to the issue

Original Article

In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts

Original Article

Phase II study of cisplatin and oral VP16 in patients with refractory or relapsed Ewing sarcoma

Original Article

Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection

Original Article

CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients

Original Article

A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

Original Article

Autophagy, cell death and sustained senescence arrest in B16/F10 melanoma cells and HCT-116 colon carcinoma cells in response to the novel microtubule poison, JG-03-14
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits